Satellite Symposia

Friday 7.9. • 8.00–9.00  • Industry-sponsored satellite symposium
Novartis Satellite symposium  
8.00–8.05 Opening words Ass prof Dan Nordström Helsinki University Hospital, Department of Rheumatology
8.05–8.25 The burden of disease and importance of treating early in SpA Lars Erik Kristensen MD PhD DMSci, CSO at the Parker Institute, Copenhagen University, Associate Professor Lund University
8.25–9.00 Structural damage in axial Spondyloarthritis Professor Desiree van der Heijde; Leiden University Medical center, Rheumatology

 

Friday 7.9. • 17.15–18.15  • Industry-sponsored satellite symposium
Roche Satellite Symposium 
Giant Cell Arteritis – A New Era in Treatment
17.15–17.20 Introduction    Chairman: Tom Pettersson, Professor, Clinic of General Internal Medicine and Rheumatology,
Helsinki University Hospital, Department of Clinical Medicine, Helsinki University
17.20–17.45 Risk Factors and Pathogenesis of GCA Carl Turesson, Professor, Senior Consultant, Rheumatology, Department of Clinical Sciences,
Malmö, Lund University, Department of Rheumatology, Skåne University Hospital
17.45–18.10 Tocilizumab in the Treatment of GCA Bhaskar Dasgupta, Professor, Clinical Director Research and Audit, Honorary Professor,
Essex University, Visiting Professor, Anglia Ruskin University, Honorary Professor at Queen Mary's University Hospital, London
18.10–18.15 Discussion
18.15 End of Symposium

 

Friday 7.9. • 17.15–18.15  • Industry-sponsored satellite symposium
Lilly RA symposium 
Pain and fatigue in RA - need for improvement?
17.15 Introduction Tore Kvien, Prof. Diakonhjemmet Hospital, Oslo
  Pain and fatigue – what does the clinical research show?t Jon Lampa, ass. Prof, Karolinska Sjukhuset, Stockholm
  JAK inhibitors as new treatment options – efficacy on patient reported outcomes Tuomas Rannio, Head of Rheumatology Dept., Central Finland Central Hospital, Jyväskylä
  Q&A (panel discussion)

 

Saturday 8.9. • 8.00–9.00 • Industry-sponsored satellite symposium
Lilly PsA symposium
Management of PsA anno 2018
8.00 Introduction - is the management of PsA optimal? Lars-Erik Kristensen, MD, PhD, Prof. Parker Institute, Frederiksberg
Laura Coates MD, PhD, MBChB, MRCP University of Oxford (video)
  PsA management in the real world: Clinical Experience from a rheumatologist & dermatologist perspective Laura Pirilä MD, PhD, Head of Rheumatology, Turku University Hospital
Tarja Mälkönen MD, PhD, Head of Dermatology, University of Helsinki
  New treatment option available – overview of benefits & safety Lars-Erik Kristensen, MD, PhD, Prof. Parker Institute, Frederiksberg
  Discussion

 

Saturday 8.9. • 8.00–9.00 • Industry-sponsored satellite symposium
Pfizer satellite symposium
Tofacitinib: new treatment option in psoriatic arthritis
7.30–8.00 Breakfast  
8.00–8.10 Introduction MD, Prof. Marjatta Leirisalo-Repo
8.10–8.30 Unmet Needs in Psoriatic Arthritis MD Joonas Rautavaara
8.30–8.50 Tofacitinib in Psoriatic Arthritis MD, Prof. Tore Kvien
8.50–9.00 Discussion & Questions
9.00 End of symposium